Kidney Tumour Biopsy: When Is It Needed and When Can It Be Avoided?
Medically reviewed by Dr. Anshuman Singh, M.S., M.Ch. Urology (Gold Medalist) · Last reviewed
A kidney tumour is detected on a CT scan or MRI, and one of the first questions patients often ask is:
“Shouldn’t we do a biopsy first to confirm whether it is cancer?”
It sounds logical. In many cancers, a biopsy is almost always performed before definitive treatment.
Kidney tumours are different.
Some renal masses should be biopsied before treatment. Others can be treated without a biopsy when imaging is sufficiently characteristic and the biopsy result would not alter management.
The key question is therefore not simply:
“Can this kidney tumour be biopsied?”
It is:
“Will the biopsy provide information that changes what we do?”
What Is a Renal Tumour Biopsy?
A renal tumour biopsy, also called a renal mass biopsy, is a procedure in which a small tissue sample is taken directly from a kidney tumour.
It is usually performed:
- Through the skin
- Under ultrasound or CT guidance
- Using local anaesthesia
- With a specialised biopsy needle
The tissue is then examined by a pathologist to determine what type of lesion is present.
For solid renal tumours, core needle biopsy is generally preferred because it provides tissue architecture and allows better histological assessment.
Why Isn't Every Kidney Tumour Biopsied?
This is one of the important differences between kidney cancer and many other cancers.
A solid kidney tumour that enhances on contrast CT or MRI may have imaging characteristics strongly suspicious for renal cell carcinoma (RCC).
If a medically fit patient has a localised renal mass and surgery is already clearly indicated, the management may remain the same irrespective of biopsy.
For example:
Biopsy shows RCC → Surgery
Biopsy is suspicious but inconclusive → Surgery may still be required
In this situation, performing a biopsy may add little to the treatment decision.
The American Urological Association continues to recommend a utility-based approach to renal mass biopsy rather than routine biopsy of every renal tumour. American Urological Association
When Is Kidney Tumour Biopsy Particularly Useful?
A biopsy becomes valuable when knowing the pathology could change the treatment strategy.
Common situations include:
1. When Active Surveillance Is Being Considered
Suppose a patient has a small renal mass and both surveillance and treatment are reasonable options.
Knowing whether the tumour represents:
- A benign lesion
- A low-grade malignancy
- A potentially more aggressive renal cancer
may help with decision-making.
This is particularly relevant when the balance between immediate intervention and surveillance is uncertain.
2. Before Kidney Tumour Ablation
Some small renal tumours can be treated with ablative techniques such as cryoablation.
Unlike surgery, ablation destroys the tumour rather than removing an intact specimen that can subsequently undergo complete pathological examination.
Therefore, establishing a diagnosis beforehand becomes particularly important.
Current guidelines recommend obtaining a renal tumour biopsy before thermal ablation. American Urological Association
3. When Imaging Is Indeterminate
Not every renal mass has typical imaging characteristics.
Sometimes CT or MRI identifies a lesion but cannot confidently determine its nature.
The differential diagnosis may include:
- Renal cell carcinoma
- Oncocytoma
- Angiomyolipoma with little visible fat
- Metastasis from another cancer
- Lymphoma
- Inflammatory lesions
- Other uncommon renal tumours
In selected cases, biopsy can prevent inappropriate treatment based solely upon an uncertain radiological diagnosis.
4. When Another Cancer Could Have Spread to the Kidney
A renal lesion in a patient with a previous or current non-urological cancer creates a different diagnostic problem.
The lesion could represent:
A new primary kidney cancer
or
Metastatic disease involving the kidney.
These conditions may require completely different treatment strategies.
A biopsy can therefore be particularly useful when the diagnosis will influence systemic therapy or the role of surgery.
5. Before Systemic Treatment When There Is No Previous Tissue Diagnosis
Patients with advanced or metastatic disease generally require histological confirmation before starting systemic anticancer therapy when no previous pathology is available.
This establishes the diagnosis and helps determine the histological subtype of kidney cancer.
Modern kidney cancer treatment increasingly depends upon accurate pathological classification.
Can Kidney Tumour Biopsy Prevent Unnecessary Surgery?
In selected patients, yes.
One reason for considering biopsy is that not every surgically removed renal mass ultimately proves to be malignant.
Benign renal tumours exist, and distinguishing them from malignant renal tumours based on imaging alone can sometimes be difficult.
If biopsy confidently demonstrates a benign lesion and the clinical and radiological findings are concordant, surgery may potentially be avoided in appropriately selected patients.
However, biopsy results must always be interpreted together with the imaging.
What Can the Biopsy Tell Us?
A successful renal tumour biopsy may provide information about:
Whether the tumour is malignant
The biopsy may establish renal cell carcinoma or another malignant process.
Histological subtype
For example:
- Clear-cell RCC
- Papillary RCC
- Chromophobe RCC
Whether another disease is present
Occasionally, the lesion may represent:
- Lymphoma
- Metastatic cancer
- An inflammatory process
- Another unusual renal pathology
This can substantially alter treatment.
Can Biopsy Determine the Tumour Grade?
Biopsy may provide information regarding tumour grade, but this needs cautious interpretation.
Kidney cancers can be heterogeneous.
One part of a tumour may look biologically different from another.
A biopsy samples only a small portion of the lesion.
Therefore, the tumour grade obtained from biopsy may occasionally underestimate the highest-grade component present elsewhere in the tumour.
This is one reason why biopsy results should not be interpreted in isolation.
Can Biopsy Reliably Diagnose an Oncocytoma?
This is more complicated.
Oncocytoma is a benign renal tumour that can resemble renal cell carcinoma on imaging.
Biopsy can sometimes strongly suggest an oncocytic neoplasm. However, distinguishing oncocytoma from certain other oncocytic renal tumours—particularly chromophobe RCC—may occasionally be difficult using a limited biopsy sample.
Therefore, a biopsy report containing terms such as:
“Oncocytic renal neoplasm”
does not necessarily mean that the diagnosis is definitively benign.
The pathological terminology and imaging findings need to be considered together.
What Does “Non-Diagnostic Biopsy” Mean?
Occasionally, the pathologist cannot establish a diagnosis from the tissue obtained.
This may happen because:
- Too little tissue was obtained
- The sample contains predominantly blood or necrosis
- The needle did not adequately sample the viable tumour
- The tumour is difficult to characterise from limited tissue
This is called a non-diagnostic biopsy.
Importantly:
A non-diagnostic biopsy does not mean that the tumour is benign.
Further evaluation may include:
- Repeat biopsy
- Continued surveillance
- Surgery
depending upon the overall clinical situation.
If the Biopsy Is Negative, Does That Completely Rule Out Cancer?
Not necessarily.
This is an important counselling point.
A biopsy samples only part of a tumour. Therefore, a benign or negative biopsy result must be interpreted in the context of:
- CT/MRI appearance
- Quality of the biopsy specimen
- Tumour size and location
- Pathology findings
- Clinical suspicion
If imaging remains highly suspicious despite a non-diagnostic or discordant biopsy, further evaluation may still be required.
Is Kidney Tumour Biopsy Dangerous?
Renal mass biopsy is generally considered a low-morbidity procedure when performed appropriately under image guidance.
Potential complications include:
- Pain
- Bleeding
- Perirenal haematoma
- Infection
- Non-diagnostic sampling
Serious complications are uncommon.
Can the Biopsy Spread Kidney Cancer?
This is one of the most common concerns patients have.
Tumour seeding along the biopsy tract has been reported, but it is considered very rare with contemporary biopsy techniques.
Modern renal tumour biopsy commonly uses a coaxial technique, which allows tissue samples to be obtained through an introducer sheath while reducing repeated passage through surrounding tissues.
Guidelines recommend the coaxial technique when performing renal tumour biopsy.
Does the Biopsy Needle Damage the Kidney?
The amount of kidney tissue affected by a properly performed renal mass biopsy is generally very small.
The procedure is specifically targeted toward the tumour rather than randomly sampling the kidney.
It should therefore not be confused with a medical renal biopsy, which is performed for diseases affecting the functioning kidney tissue itself.
The two procedures answer completely different clinical questions.
Kidney Tumour Biopsy vs Kidney Biopsy: Are They the Same?
Not exactly.
Renal tumour biopsy
Targets a mass or tumour to determine what the lesion represents.
Medical renal biopsy
Samples functioning renal tissue to investigate conditions such as:
- Glomerulonephritis
- Nephrotic syndrome
- Unexplained renal dysfunction
- Other medical kidney diseases
When discussing kidney cancer, we are referring specifically to a renal mass/tumour biopsy.
When Can Kidney Tumour Biopsy Be Avoided?
A biopsy may reasonably be omitted when its result is unlikely to change management.
A typical example is:
A medically fit patient has a localised, solid enhancing renal tumour highly suspicious for RCC.
After appropriate counselling, surgery has been selected.
If the plan remains surgical excision regardless of the biopsy result, routine preoperative biopsy may not provide meaningful additional benefit.
This is why many patients undergo partial nephrectomy without a previous biopsy.
That does not mean a diagnostic step has been missed.
It reflects a deliberate clinical decision based upon the imaging findings and planned management.
Do You Need a Biopsy Before Partial Nephrectomy?
Not routinely.
Partial nephrectomy removes the tumour and provides the entire surgical specimen for definitive pathological examination.
The final pathology then determines:
- Whether the lesion is malignant or benign
- Histological subtype
- Tumour grade
- Pathological stage
- Surgical margin status
- Other relevant pathological features
Therefore, a preoperative biopsy is generally most useful when its result could prevent surgery or alter the treatment strategy.
What About a Very Small Kidney Tumour?
This is where biopsy can become particularly useful.
Consider a 1.5 cm renal mass in an older patient with several medical problems.
The realistic options might include:
Active surveillance
or
Treatment
If biopsy demonstrates a benign lesion or a tumour with favourable biological characteristics, surveillance may become more attractive.
Conversely, evidence of more concerning pathology may strengthen the rationale for intervention.
The value of biopsy therefore increases when there is genuine uncertainty about which management pathway to choose.
What About a Large Kidney Tumour?
A larger renal mass with classical radiological features and a clear indication for surgical removal may not require biopsy before surgery.
However, size alone should not determine the decision.
Biopsy may still be important if:
- Lymphoma is suspected
- Metastatic disease is possible
- Another diagnosis is being considered
- Systemic therapy is planned before surgery
- Histological confirmation would alter management
Again, the principle remains:
Biopsy when the answer matters.
The Most Important Question Before Ordering a Biopsy
Before performing a renal tumour biopsy, I find it useful to frame the decision very simply:
“What will we do if the biopsy shows cancer?”
Then:
“What will we do if the biopsy is benign?”
And finally:
“What will we do if the biopsy is inconclusive?”
If all three answers lead to exactly the same treatment, the value of biopsy may be limited.
If the answers lead to different management pathways, biopsy may be extremely useful.
Kidney Tumour Evaluation in Lucknow
At Uro-Onco Connect, Lucknow, renal masses are evaluated using the entire clinical picture rather than automatically proceeding to either biopsy or surgery.
Assessment may include:
Contrast CT/MRI → tumour size and complexity → kidney function → opposite kidney → patient age and fitness → likelihood of malignancy → whether biopsy will alter management → surveillance versus treatment → kidney-preserving surgery where appropriate
For patients requiring intervention, treatment options may include robotic partial nephrectomy, radical nephrectomy or ablative treatment, depending upon tumour characteristics and individual circumstances.
For selected small renal masses, active surveillance with or without renal tumour biopsy may also be appropriate.
The Key Message
A kidney tumour does not always need to be biopsied before treatment.
But that does not mean kidney tumour biopsy is unimportant.
It is particularly valuable when pathology can help decide between:
Treatment vs surveillance
Surgery vs ablation
or when the diagnosis itself is uncertain.
The most useful way to think about renal tumour biopsy is therefore:
Do not biopsy simply because a tumour exists.
Biopsy when knowing the pathology is likely to change the management.
About Dr. Anshuman Singh
Dr. Anshuman Singh
M.S., M.Ch. Urology (Gold Medalist)
Fellowship – Uro-Oncology & Robotic Surgery (USI, Intuitive Certified)
Visiting Fellow – Robotic Uro-Oncology (Fundació Puigvert, Spain)
Clinical Observer – Robotic Pelvic Oncology (University College Hospitals, London)
Vice Chairperson – Uro-Oncology & Robotic Surgery
Chandan Cancer Institute, Chandan Hospital
Lucknow
Dr. Anshuman Singh's clinical practice focuses on Uro-Oncology and Robotic Surgery, including kidney, prostate, bladder, testicular and penile cancers.
Patients diagnosed with a kidney tumour or indeterminate renal mass can seek specialist evaluation regarding renal tumour biopsy, active surveillance, robotic partial nephrectomy and other kidney cancer treatment options.
References
- European Association of Urology. EAU Guidelines on Renal Cell Carcinoma. EAU Guidelines Office, Arnhem, The Netherlands.
- Campbell SC, Clark PE, Chang SS, et al. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline. J Urol. 2021;206:199–208.
- Marconi L, Dabestani S, Lam TB, et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol. 2016;69:660–673.
- Volpe A, Finelli A, Gill IS, et al. Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol. 2012;62:491–504.
Tags
Written by
Dr. Anshuman Singh
Uro-Oncologist & Robotic Surgeon · M.S., M.Ch. Urology (Gold Medalist)